Why the study?
Does the concomitant use of pyrazole compounds and coumarin derivatives increase the risk of sudden bleeding and altered prothrombin activity?
Does the concomitant use of pyrazole compounds and coumarin derivatives increase the risk of sudden bleeding and altered prothrombin activity?
Concomitant use of pyrazole compounds like phenylbutazone with coumarin anticoagulants can potentiate anticoagulant effects, leading to sudden bleeding.
Answers are grounded in this paper and cite their sources.
May warrant caution with pyrazole-coumarin co-use; leaves open the interaction's magnitude in contemporary cohorts.
COUMARIN DERIVATIVESare frequently employed for short-term or long-term anticoagulation therapy for thrombo-embolic disorders and disturbances in intravascular clotting. Sudden bleeding, with an alarming alteration in prothrombin activity for no obvious or accountable reason, in individuals who have been stabilized for long periods, has been reported previously. Reports of such occurrences seldom refer to the concomitant use of certain pyrazole compounds (ie, phenylbutazone and oxyphenbutazone) with the coumarin-type anticoagulants. Nor do all manufacturers of these drugs mention the possibility in their brochures. One manufacturer of warfarin sodium mentions phenylbutazone as "an exogenous factor which may be responsible for an increased prothrombin time response". A manufacturer of phenylbutazone and related drugs has indicated that a change in their literature and labeling which adds this precaution to the directions is under consideration by the pertinent federal agency.2 These drugs are not uncommonly used in individuals who have arthritis or gout complicated
No takes yet. Share an insight, caveat, or question.
Saul L. Fox (1964) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: